Cargando…

(18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment

INTRODUCTION: Dysregulation of cerebral glucose consumption, alterations in cerebrospinal fluid (CSF) biomarkers, and cognitive impairment have been reported in patients with obstructive sleep apnoea (OSA). On these bases, OSA has been considered a risk factor for Alzheimer’s disease (AD). This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Mariana, Mari, Luisa, Chiaravalloti, Agostino, Paoli, Barbara, Nuccetelli, Marzia, Izzi, Francesca, Giambrone, Maria Pia, Camedda, Riccardo, Bernardini, Sergio, Schillaci, Orazio, Mercuri, Nicola Biagio, Placidi, Fabio, Liguori, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468130/
https://www.ncbi.nlm.nih.gov/pubmed/35608659
http://dx.doi.org/10.1007/s00415-022-11182-z
_version_ 1784788344607080448
author Fernandes, Mariana
Mari, Luisa
Chiaravalloti, Agostino
Paoli, Barbara
Nuccetelli, Marzia
Izzi, Francesca
Giambrone, Maria Pia
Camedda, Riccardo
Bernardini, Sergio
Schillaci, Orazio
Mercuri, Nicola Biagio
Placidi, Fabio
Liguori, Claudio
author_facet Fernandes, Mariana
Mari, Luisa
Chiaravalloti, Agostino
Paoli, Barbara
Nuccetelli, Marzia
Izzi, Francesca
Giambrone, Maria Pia
Camedda, Riccardo
Bernardini, Sergio
Schillaci, Orazio
Mercuri, Nicola Biagio
Placidi, Fabio
Liguori, Claudio
author_sort Fernandes, Mariana
collection PubMed
description INTRODUCTION: Dysregulation of cerebral glucose consumption, alterations in cerebrospinal fluid (CSF) biomarkers, and cognitive impairment have been reported in patients with obstructive sleep apnoea (OSA). On these bases, OSA has been considered a risk factor for Alzheimer’s disease (AD). This study aimed to measure cognitive performance, CSF biomarkers, and cerebral glucose consumption in OSA patients and to evaluate the effects of continuous positive airway pressure (CPAP) treatment on these biomarkers over a 12-month period. METHODS: Thirty-four OSA patients and 34 controls underwent (18)F-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG PET), cognitive evaluation, and CSF analysis. A subgroup of 12 OSA patients treated with beneficial CPAP and performing the 12-month follow-up was included in the longitudinal analysis, and cognitive evaluation and (18)F-FDG PET were repeated. RESULTS: Significantly reduced glucose consumption was observed in the bilateral praecuneus, posterior cingulate cortex, and frontal areas in OSA patients than controls. At baseline, OSA patients also showed lower β-amyloid(42) and higher phosphorylated-tau CSF levels than controls. Increased total tau and phosphorylated tau levels correlated with a reduction in brain glucose consumption in a cluster of different brain areas. In the longitudinal analysis, OSA patients showed an improvement in cognition and a global increase in cerebral (18)F-FDG uptake. CONCLUSIONS: Cognitive impairment, reduced cerebral glucose consumption, and alterations in CSF biomarkers were observed in OSA patients, which may reinforce the hypothesis of AD neurodegenerative processes triggered by OSA. Notably, cognition and brain glucose consumption improved after beneficial CPAP treatment. Further studies are needed to evaluate the long-term effects of CPAP treatment on these AD biomarkers.
format Online
Article
Text
id pubmed-9468130
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94681302022-09-14 (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment Fernandes, Mariana Mari, Luisa Chiaravalloti, Agostino Paoli, Barbara Nuccetelli, Marzia Izzi, Francesca Giambrone, Maria Pia Camedda, Riccardo Bernardini, Sergio Schillaci, Orazio Mercuri, Nicola Biagio Placidi, Fabio Liguori, Claudio J Neurol Original Communication INTRODUCTION: Dysregulation of cerebral glucose consumption, alterations in cerebrospinal fluid (CSF) biomarkers, and cognitive impairment have been reported in patients with obstructive sleep apnoea (OSA). On these bases, OSA has been considered a risk factor for Alzheimer’s disease (AD). This study aimed to measure cognitive performance, CSF biomarkers, and cerebral glucose consumption in OSA patients and to evaluate the effects of continuous positive airway pressure (CPAP) treatment on these biomarkers over a 12-month period. METHODS: Thirty-four OSA patients and 34 controls underwent (18)F-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG PET), cognitive evaluation, and CSF analysis. A subgroup of 12 OSA patients treated with beneficial CPAP and performing the 12-month follow-up was included in the longitudinal analysis, and cognitive evaluation and (18)F-FDG PET were repeated. RESULTS: Significantly reduced glucose consumption was observed in the bilateral praecuneus, posterior cingulate cortex, and frontal areas in OSA patients than controls. At baseline, OSA patients also showed lower β-amyloid(42) and higher phosphorylated-tau CSF levels than controls. Increased total tau and phosphorylated tau levels correlated with a reduction in brain glucose consumption in a cluster of different brain areas. In the longitudinal analysis, OSA patients showed an improvement in cognition and a global increase in cerebral (18)F-FDG uptake. CONCLUSIONS: Cognitive impairment, reduced cerebral glucose consumption, and alterations in CSF biomarkers were observed in OSA patients, which may reinforce the hypothesis of AD neurodegenerative processes triggered by OSA. Notably, cognition and brain glucose consumption improved after beneficial CPAP treatment. Further studies are needed to evaluate the long-term effects of CPAP treatment on these AD biomarkers. Springer Berlin Heidelberg 2022-05-24 2022 /pmc/articles/PMC9468130/ /pubmed/35608659 http://dx.doi.org/10.1007/s00415-022-11182-z Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Fernandes, Mariana
Mari, Luisa
Chiaravalloti, Agostino
Paoli, Barbara
Nuccetelli, Marzia
Izzi, Francesca
Giambrone, Maria Pia
Camedda, Riccardo
Bernardini, Sergio
Schillaci, Orazio
Mercuri, Nicola Biagio
Placidi, Fabio
Liguori, Claudio
(18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
title (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
title_full (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
title_fullStr (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
title_full_unstemmed (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
title_short (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
title_sort (18)f-fdg pet, cognitive functioning, and csf biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468130/
https://www.ncbi.nlm.nih.gov/pubmed/35608659
http://dx.doi.org/10.1007/s00415-022-11182-z
work_keys_str_mv AT fernandesmariana 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT mariluisa 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT chiaravallotiagostino 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT paolibarbara 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT nuccetellimarzia 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT izzifrancesca 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT giambronemariapia 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT cameddariccardo 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT bernardinisergio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT schillaciorazio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT mercurinicolabiagio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT placidifabio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment
AT liguoriclaudio 18ffdgpetcognitivefunctioningandcsfbiomarkersinpatientswithobstructivesleepapnoeabeforeandaftercontinuouspositiveairwaypressuretreatment